Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells

被引：0

作者：

Keller, Alexandra ^{[1
,2
]}

Peter, Barbara ^{[1
,2
]}

Zuber, Johannes ^{[3
]}

Staber, Philipp Bernhard ^{[2
]}

Bettelheim, Peter ^{[4
]}

Valent, Peter ^{[1
,2
]}

Hadzijusufovic, Emir ^{[1
,2
,5
]}

机构：

[1] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria

[2] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria

[3] Res Inst Mol Pathol IMP, Vienna, Austria

[4] Elisabethinen Hosp, Dept Med 1, Linz, Austria

[5] Univ Vet Med Vienna, Internal Med, Small Anim Clin, Dept Compan Anim & Horses, Vienna, Austria

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
M O Holmström
M D Hjortsø
S M Ahmad
Ö Met
E Martinenaite
C Riley
P Straten
I M Svane
H C Hasselbalch
M H Andersen
Leukemia, 2017, 31 : 495 - 498
[22] Identification of AIM2 as a downstream target of JAK2V617F
Liew E.L.
Araki M.
Hironaka Y.
Mori S.
Tan T.Z.
Morishita S.
Edahiro Y.
Ohsaka A.
Komatsu N.
Experimental Hematology & Oncology, 5 (1)
[23] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
Cheng, Zhiyong
Fu, Jianzhu
Liu, Guimin
Zhang, Lijun
Xu, Qian
Wang, Su-yun
LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203
[24] Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer
Hong, Seong Hwi
Eun, Jung Woo
Choi, Sung Kyung
Shen, Qingyu
Choi, Wahn Soo
Han, Jeung-Whan
Nam, Suk Woo
You, Jueng Soo
ONCOTARGET, 2016, 7 (22) : 32628 - 32640
[25] A case of very rare co-occurrence of POEMS syndrome and JAK2 V617F positive MPN
Alaikov, Tzvetan
Angelova, Svetlana
Hristova, Julieta
Ivanova, Milena
Shivarov, Velizar
JOURNAL OF HEMATOPATHOLOGY, 2018, 11 (01) : 23 - 26
[26] JAK2 V617F Allele Burden in Non-CML Classical Subtypes of Myeloproliferative Neoplasms (MPN)
Gober-Wilcox, J.
Vennapusa, B.
Pierce, J.
Vasef, M. A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 581 - 581
[27] A case of very rare co-occurrence of POEMS syndrome and JAK2 V617F positive MPN
Tzvetan Alaikov
Svetlana Angelova
Julieta Hristova
Milena Ivanova
Velizar Shivarov
Journal of Hematopathology, 2018, 11 : 23 - 26
[28] Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors
Guo, Yong
Zou, Yurong
Chen, Yong
Deng, Dexin
Zhang, Zihao
Liu, Kongjun
Tang, Minghai
Yang, Tao
Fu, Suhong
Zhang, Chufeng
Si, Wenting
Ma, Ziyan
Zhang, Shunjie
Peng, Bin
Xu, Dingguo
Chen, Lijuan
BIOORGANIC CHEMISTRY, 2023, 132
[29] Kinase Domain Mutations in JAK2V617F Confer Resistance to the Novel JAK2 Inhibitor Ruxolitinib
Deshpande, Anagha
Reddy, Mamatha M.
Schade, Georg
Ray, Arghya
Chowdary, Tirumala K.
Griffin, James D.
Sattler, Martin
BLOOD, 2011, 118 (21) : 61 - 61
[30] WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
Verstovsek, Srdan
Manshouri, Taghi
Quintas-Cardama, Alfonso
Harris, David
Cortes, Jorge
Giles, Francis J.
Kantarjian, Hagop
Priebe, Waldemar
Estrov, Zeev
CLINICAL CANCER RESEARCH, 2008, 14 (03) : 788 - 796

← 1 2 3 4 5 →